EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges

Shunzhen Zheng, Siew Wee Chan iD, Fei Liu, Jun Liu, Pierce Kah Hoe Chow, Han Chong Toh, Wanjin Hong

Cancers · 20.04.2024 · 16 (8) · 1582

DOI: 10.3390/cancers16081582 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 20.04.2024. Verfasst von Shunzhen Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Biopharmaceuticals, Postdoctoral Scientific Research Workstation, Shandong Academy of Pharmaceutical Science, Jinan 250098, China. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shandong Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for ~90% of liver neoplasms. It is the second leading cause of cancer-related deaths and the seventh most common cancer worldwide. Although there have been rapid developments in the treatment of HCC over the past decade, the incidence and mortality rates of HCC remain a challenge. With the widespread use of the hepatitis B vaccine and antiviral therapy, the etiology of HCC is shifting more toward metabolic-associated steatohepatitis (MASH). Early-stage HCC can be treated with potentially curative strategies such as surgical resection, liver transplantation, and radiofrequency ablation, improving long-term survival. However, most HCC patients, when diagnosed, are already in the intermediate or advanced stages. Molecular targeted therapy, followed by immune checkpoint inhibitor immunotherapy, has been a revolution in HCC systemic treatment. Systemic treatment of HCC especially for patients with compromised liver function is still a challenge due to a significant resistance to immune checkpoint blockade, tumor heterogeneity, lack of oncogenic addiction, and lack of effective predictive and therapeutic biomarkers.

Schlagwörter

Stichwörter der Autor:innen

genetic alterationshepatocellular carcinomaimmunotherapymolecular targeted therapy

Autor:innen und Institutionen

  • Key Laboratory of Biopharmaceuticals, Postdoctoral Scientific Research Workstation, Shandong Academy of Pharmaceutical Science, Jinan 250098, China.
  • Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Singapore 138673, Singapore.
  • Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
  • Division of Surgery and Surgical Oncology, National Cancer Centre, Singapore 169610, Singapore.
  • Academic Clinical Programme for Surgery, Duke-NUS Medical School, Singapore 169857, Singapore.
  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore 168583, Singapore.

ORCID-Profile: Siew Wee Chan

Förderung

  • National Natural Science Foundation of China
  • Shandong Provincial Natural Science Foundation

Zitieren

APA

Zheng, S., Chan, S. W., Liu, F., Liu, J., Chow, P. K. H., Toh, H. C., & Hong, W. (2024). Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges. Cancers, 16(8), 1582. https://doi.org/10.3390/cancers16081582

Vancouver

Zheng S, Chan SW, Liu F, Liu J, Chow PKH, Toh HC, et al. Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges. Cancers. 2024;16(8):1582. doi:10.3390/cancers16081582

BibTeX
@article{Zheng2024,
  author = {Zheng, Shunzhen and Chan, Siew Wee and Liu, Fei and Liu, Jun and Chow, Pierce Kah Hoe and Toh, Han Chong and Hong, Wanjin},
  title = {Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {8},
  pages = {1582},
  doi = {10.3390/cancers16081582}
}
Kostenlos starten →